Clinical Trial Radar

Name: Changes in Taste Perception, Eating Habits, and Other Behavioral Aspects Associated With the Use of GLP-1 Receptor Agonists in Patients Undergoing Weight Loss Treatment: A Retrospective Observational Study.
Creator: San Raffaele Telematic University
Published: 2025-11-14
License: https://www.clinicaltrials.gov/about-site/terms-conditions#availability

beta

Trial Radar AI Trial Candidate or Patient Patient Caregiver Healthcare Pro Biotech Pro Biotech Investor Researcher Other
	Clinical Trial NCT07229170 (GLP1-TASTE) for Obesity & Overweight, Taste Alterations, Weight Loss, Eating Behavior Changes is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.

One study matched filter criteria

Card View

Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients (GLP1-TASTE) 150 Observational Dietary

Not yet recruiting

Clinical Trial NCT07229170 (GLP1-TASTE) is an observational study for Obesity & Overweight, Taste Alterations, Weight Loss, Eating Behavior Changes and is currently not yet recruiting. Enrollment is planned to begin on December 1, 2025 and continue until the study accrues 150 participants. Led by San Raffaele Telematic University, this study is expected to complete by January 1, 2028. The latest data from ClinicalTrials.gov was last updated on November 14, 2025.

Brief Summary

This observational retrospective study aims to evaluate changes in taste perception, eating habits, and behavioral aspects in adults treated with GLP-1 receptor agonists for weight loss. Participants include adults aged 18-60 receiving treatment at specialized nutrition centers in Italy. Data are collected from clinical records, dietary questionnaires, and metabolic assessments before and after at least 12 weeks of G...Show More

Detailed Description

This retrospective observational study investigates changes in taste perception, eating habits, and other behavioral aspects associated with the use of GLP-1 receptor agonists in patients undergoing treatment for weight loss. The study includes adults aged 18-60 years who have been treated at specialized nutrition centers in Italy during 2025-2026. Data are collected retrospectively from clinical records, dietary que...Show More

Official Title

Changes in Taste Perception, Eating Habits, and Other Behavioral Aspects Associated With the Use of GLP-1 Receptor Agonists in Patients Undergoing Weight Loss Treatment: A Retrospective Observational Study.

Conditions

Obesity & OverweightTaste AlterationsWeight LossEating Behavior Changes

Publications

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: ...

Other Study IDs

GLP1-TASTE

NCT ID Number

NCT07229170

Start Date (Actual)

2025-12-01

Last Update Posted

2025-11-14

Completion Date (Estimated)

2028-01-01

Enrollment (Estimated)

150

Study Type

Observational

Status

Not yet recruiting

Keywords

GLP-1 agonists
Obesity treatment
Weight loss
Taste perception
Eating habits
Observational study

Arms / Interventions

Participant Group/Arm

Intervention/Treatment

GLP-1 Agonist Treated Patients

This cohort includes adult patients aged 18-60 who have been treated with GLP-1 receptor agonists such as semaglutide or tirzepatide for weight loss in specialized nutrition centers in Italy. The study collects retrospective data on changes in taste perception, eating habits, body composition, and treatment adherence over a minimum duration of 12 weeks of therapy. No interventional treatments are administered as part...Show More

N/A

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in taste perception and food preferences	Assessment of patients' taste perception changes and shifts in eating habits using validated questionnaires and behavioral surveys.	From baseline to 12 weeks after GLP-1 agonist treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in body weight	Measured in kilograms to assess weight loss effectiveness.	From baseline to 12 weeks after treatment
Gastrointestinal side effects	Recording of nausea, vomiting, diarrhea, or other GI symptoms via patient reports.	Throughout the treatment period
Treatment adherence	Assessment of continued use and discontinuation reasons of GLP-1 agonists.	Throughout the study duration

Participation Assistant

Eligibility Criteria

Inclusion: Adults aged 18-60 years diagnosed with obesity and undergoing treatment with GLP-1 receptor agonists such as semaglutide or tirzepatide. Must have clinical records and dietary data available for at least 12 weeks of treatment.

Exclusion: Patients with conditions affecting taste independent of GLP-1 treatment, severe comorbidities, or inability to provide consent and data.

San Raffaele Telematic University

Study Responsible Party

Mauro Lombardo, Principal Investigator, Full professor in Human Nutrition, San Raffaele Telematic University

Study Central Contact

Contact: Mauro Lombardo, MD, +393899740197, [email protected]

1 Study Locations in 1 Countries

Italy

San Raffaele Open University, Rome, 00166, Italy